Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06013995 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
A Phase 1 study of Lupus, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 20
- Study locations
NCT06013995: Recruiting Phase 1 study of Lupus, sponsored by Bristol-Myers Squibb.
NCT06013995 is a Phase 1 study of Lupus that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 44 participants, below the 282-participant average among 13 other Lupus trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06013995, a Phase 1 study of Lupus, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate safety, drug levels and drug effects on cells and organs of the body, after receiving multiple increasing doses of BMS-986326 via intravenous (IV) infusion or subcutaneous (SC) injection, in participants with different forms of lupus.
Conditions Studied
Interventions
- DRUG BMS-986326
- OTHER Placebo for BMS-986326
Study Locations (20)
Other
- Local Institution - 0072 - Sofia
- Local Institution - 0044 - Berlin
- Local Institution - 0071 - Dessau
- Local Institution - 0047 - Dresden
- Local Institution - 0077 - Chihuahua City
Florida
- Clinical Research of West Florida, Inc. (Clearwater) - Clearwater
- Clinical Research of West Florida - Tampa
Texas
- Allen Arthritis - Allen
- Metroplex Clinical Research Center - Dallas
DIF
- Local Institution - 0073 - Cuauhtémoc, Ciudad de México
- Local Institution - 0068 - Mexico City
California
- Local Institution - 0048 - San Diego
Georgia
- North Georgia Rheumatology - Lawrenceville
Kentucky
- Skin Sciences - Louisville
Nevada
- Local Institution - 0062 - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2026-04-12 |
| Phase | Phase 1 |
What NCT06013995 shows while recruiting
NCT06013995 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 282-participant average among 13 other Lupus trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Lupus appearing as the primary indexed condition, and to 2 interventions - of which BMS-986326 is the first listed.
NCT06013995 names 20 study sites across 13 states, led by Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06013995 about?
NCT06013995 is a clinical study titled "A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus". The purpose of this study is to evaluate safety, drug levels and drug effects on cells and organs of the body, after receiving multiple increasing doses of BMS-986326 via intravenous (IV) infusion or subcutaneous (SC) injection, in participants with different forms of lupus.
What is the current status of trial NCT06013995?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2023-09-21. Estimated completion is 2026-04-12.
What conditions does trial NCT06013995 study?
This clinical trial studies the following conditions: Lupus.
What interventions are being tested in trial NCT06013995?
The interventions under investigation include: BMS-986326 (DRUG), Placebo for BMS-986326 (OTHER).
Who is sponsoring clinical trial NCT06013995?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06013995 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Kentucky, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06013995's enrollment target sits among peer trials
44 9th of 13 higher than 5 of 13 other Lupus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lupus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
-
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus
COMPLETED · Phase 1
-
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI